Higher thiazide doses may reduce kidney stone events, suggests JAMA study

Higher thiazide doses are associated with greater reductions in urine calcium, which in turn correlate with fewer symptomatic kidney stone events, according to a Vanderbilt University Medical Center (VUMC) study published in JAMA Network Open.

Thiazide diuretics, commonly prescribed to prevent kidney stone recurrence, are drugs that act directly on the kidneys to promote diuresis (urine flow) by inhibiting the sodium/chloride cotransporter located in the distal convoluted tubule of a nephron (the functional unit of a kidney). Thiazides are also used as a common treatment for high blood pressure and to clear fluid from the body in conditions such as heart failure.

First author Ryan Hsi, MD, FACS, associate professor in the Department of Urology at VUMC, said the study data help explain the findings of the multicenter Hydrochlorothiazide for Kidney Stone Recurrence Prevention (NOSTONE) trial, which reported that hydrochlorothiazide did not reduce recurrence of kidney stone events.

“In light of our research, the calcium reductions in that study were modest and likely insufficient to affect recurrence risk,” Hsi said.

“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence. It may be beneficial to monitor calcium excretion while on thiazide therapy to adjust dose and diet to attain an adequate reduction in urine calcium.”

A total of 634 participants were studied, revealing significant associations between higher thiazide doses and urine calcium reductions greater than those achieved in the NOSTONE trial, where participants took different doses of hydrochlorothiazide.

For next steps, the researchers are interested in understanding which subtypes of thiazides and their dosing work best, and how best to optimize medication adherence, since these therapies are often administered long term.

Reference:

Hsi RS, Yan PL, Maalouf NM, et al. Thiazide Dose, Urine Calcium, and Symptomatic Kidney Stone Events. JAMA Netw Open. 2024;7(8):e2428953. doi:10.1001/jamanetworkopen.2024.28953

Powered by WPeMatico

Inhaler misuse tied to mismanagement of COPD symptoms, increased exacerbations, suggests study

Inhaler misuse leading to inadequate medication delivery impacts a person’s ability to manage symptoms of chronic obstructive pulmonary disease (COPD), and additional education about proper inhaler use is needed to improve health outcomes, according to two new articles. The articles are published in the July 2024 issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, a peer-reviewed, open-access journal.

COPD comprises several conditions, including chronic bronchitis and emphysema, and can be caused by irritants like smoke or pollution and genetics. The disease affects more than 30 million Americans, yet awareness of the disease’s symptoms, methods to reduce risk, and disease management remains poor. Symptoms, which include breathlessness, fatigue, and chronic cough, are primarily treated using inhaled medications.

In a new study, “Prevalence of Critical Errors and Insufficient Peak Inspiratory Flow in Patients Hospitalized With COPD in a Department of General Internal Medicine: A Cross-Sectional Study,” the authors examined how often inhalers were misused by patients hospitalized with COPD over the course of nine months at Fribourg Hospital in Switzerland.

Inhaler misuse was categorized as either a critical error in inhalation technique or insufficient peak inspiratory flow. These errors result in a lesser dose of medication reaching the person’s lungs, which impacts the person’s ability to manage their symptoms and can lead to increased exacerbations.

“Misuse of inhalers is common, and in our study, we found that approximately two-thirds of inhalers were misused,” said Gaël Grandmaison, M.D., an assistant physician in internal medicine at University and Hospital of Fribourg in Fribourg, Switzerland. “If an inhaler was misused, a physiotherapist conducted up to three teaching sessions with the patient. These sessions helped reduce the number of critical errors in inhaler use. However, despite this education, more than one in 10 inhalers continued to be used suboptimally, either due to an inability to generate sufficient inspiratory effort or because the inhaler was unsuitable for the patient’s characteristics. These results highlight the importance of regular therapeutic education, assessing the patient’s ability to generate a sufficient inspiratory effort, and selecting an inhaler suited to the patient’s characteristics.”

In a perspective article, “Real-World Use of Inhaled COPD Medications: the Good, the Bad, the Ugly,” the author discusses the decreased effectiveness of inhaled medications as the result of inhaler misuse (often due to intricacies and multiple steps required to use the inhaler) and the high cost of inhaler-based therapies. The author also highlights several advances in inhaler use, including the ability to combine therapies and to choose the right inhaler based on patient-centered decisions.

“Education is key to increasing the effectiveness of inhaled medications, and many clinicians – and often even the patients themselves – are unaware that patients are having difficulty getting enough medication into their lungs,” said Valerie G. Press, M.D., MPH, an associate professor of medicine at the University of Chicago. “Additional inhaler technique education is needed to ensure patients are using the device correctly, especially when multiple inhaled medications are prescribed. Additional education, supported by the necessary resources, would help ensure patients are receiving optimal treatment and avoiding adverse health outcomes.”

Reference:

Grandmaison G, Grobéty T, Vaucher J, Hayoz D, Suter P. Prevalence of critical errors and insufficient peak inspiratory flow in patients hospitalized with COPD in a department of general internal medicine: a cross-sectional study. Chronic Obstr Pulm Dis. 2024; 11(4): 406-415. doi: http://doi.org/10.15326/jcopdf.2024.0505

Powered by WPeMatico

From Colonial to Indian Legacy: Health Ministry asks AIIMS, INIs to Design Appropriate Dress Code for Convocation Ceremony

New Delhi: Referring to the “Panch Pran” (five resolutions) enunciated by the Prime Minister, the Union Ministry of Health and Family Welfare has directed Central Government medical institutes and hospitals to design an appropriate Indian dress code for the Convocation Ceremony of their Institute based on local traditions of the State in which the Institute is located.

In a circular issued to the Head of all the Central Govt. Hospitals, AIIMS, INIs, Central Government Medical Teaching Institutes, the Under Secretary to the Government of India mentioned that the proposal in this regard should be submitted to the Ministry through their respective Divisions of the Ministry for consideration and approval of the Health Secretary.

Referring to the “Panch Pran(five resolutions)” enunciated by the Hon’ble Prime Minister, the Health Ministry mentioned in a circular, “In this regard, it is observed that currently as a matter of practice black robe and cap is being used during convocation by various Institutes of the Ministry. This attire originated in the middle Ages in Europe and was introduced by the British in all their colonies. The above tradition is a colonial legacy which needs to be changed.”

“Accordingly it has been decided by the Ministry that the various Institutes of the Ministry including AIIMS /INIs enagged in imparting medical education will design appropriate India dress code for the Convocation Ceremony of their Institute’ based on local traditions of the State in which the Institute is located . The proposal to this effect should be submitted to the Ministry through their respective Divisions of Ministry for consideration and approval of Secretary (Health),” it added.

Back in 2022, Prime Minister Narendra Modi announced his resolution to cleanse the country of corruption and nepotism asking people to have ‘nafrat’ (hatred) for these twin evils that go beyond politics, as he set a ‘Panch Pran’ (five resolves) target to make India a developed nation in 25 years.

He had spelt out the the five pledges as a resolve for a developed India; removing any trace of the colonial mindset; taking pride in our legacy; our strength of unity; and fulfilling the duties of citizens, which include prime minister and chief ministers as well.

Also Read: AIIMS Bhubaneswar notifies on Security Fees, Dress Code for its 4th Convocation, details

Powered by WPeMatico

Bengaluru Doctor attacked by patient with scissors during treatment

Bengaluru: In a shocking incident, a doctor at a private hospital in Bettadasanapura, Bengaluru was allegedly assaulted by a Nepalese man who was brought by the police for treatment.

The 35-year-old cook was reportedly high on drugs, the attack has raised concerns about safety in healthcare settings amid rising drug-related violence. 

As per  The Hindu reports, the accused was identified as a native of Nepal and was detained by the police for causing a disturbance on the road while under the influence of drugs.

The accused, Ashish, had injured himself by banging his head against a car. After that, the police brought him to the hospital and handed him over to the doctors and they left. Dr. Nagendrappa admitted the accused as an injured patient and provided treatment for his injuries on Monday night.

However, when two nurses were attending to his wounds and administering IV fluids, he became aggressive. He ransacked the room, grabbed a knife, and charged at the nurses.

The two nurses fled after the accused who was under the influence of drugs lunged at them with a pair of scissors. Hearing the commotion, Dr. Nagendrappa rushed to assist and attempted to calm him down.

Also Read:Kalwa Hospital Doctors, Nurse manhandled by attendants over improper treatment

However, his behaviour quickly escalated into violence. He attacked Dr Nagendrappa and reportedly slashed his lips and hands with the scissors and even bit him.

Others rushed to Dr Nagendrappa’s aid and, after a struggle, managed to restrain the accused before alerting the police. 

The police arrived at the hospital and handcuffed the accused to ensure he could continue his treatment at the hospital. Later they took him into custody where he is expected to face charges related to assault.

Based on a complaint, the police filed a case against the accused on Tuesday. He was charged under the Karnataka Prohibition of Violence against Medicare Service Personnel and Damage to Property in Medicare Service Institutions Act, 2009, as well as under Section 115 (voluntarily causing hurt) of the BNS Act. The case is now under further investigation.

Also Read: ‘Kicked, punched, tortured’: 1st-year PGIMS BDS student alleges assault, harassment by MD anatomy medico for past 7 months, accused arrested

Powered by WPeMatico

NPPA Revises Ceiling Price of 4 Scheduled Formulation, Detail

New Delhi: Through a recent notice, after considering the Wholesale Price Index (WPI) impact at 0.00551% for the year 2024, the National Pharmaceutical Pricing Authority (NPPA) has revised the ceiling price of 4 scheduled formulations including Valganciclovir 450mg, Metoprolol 25mg, Lamivudine 100 mg, and Montelukast 4 mg.

This matter was discussed in the 125th Authority meeting dated July 25, 2024, where the expert panel revised the ceiling price of 4 scheduled formulations.

“Ceiling Price” refers to a price fixed by the Government for Scheduled Formulations in accordance with the provisions of the drugs (prices control) order, 2013. The ceiling price is the maximum price to the retailer (excluding taxes, if any) for the given product.

The notice stated that in an implementation of directions of review order issued by the Department of Pharmaceuticals (DOP) under para 31 of Drugs (Prices Control) Order, 2013 vide order specified in column (7) of the table below and in the exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S.O. 5249(E) dated 11th November 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. and date specified in Column (8) of the table, the National Pharmaceutical Pricing Authority, has fixed/revised the price including WPI impact @0.00551% for the year 2024 as specified in column (6) of the table herein below as ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Sl.

No.

Medicines

Dosage Form & Strength

Unit

Ceiling Price under NLEM, 2022 (Rs.)

Revised Ceiling price based on Review Order & considering WPI @0.00551%

(Rs.)

Review Order number and date

Existing SO number and date

(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

1.

Valganciclovir

Tablet 450 mg

1

Tablet

400.73

408.27

31015/19/2023-

Pricing dated 27.05.2024

1547(E) dated 26.03.2024

(Sl. No. 668)

2.

Metoprolol

Tablet 25 mg

1

Tablet

4.20

4.25

31015/14/2023-

Pricing dated 27.05.2024

1547(E) dated 26.03.2024

(Sl. No. 446)

3.

Lamivudine

Tablet 100 mg

1

Tablet

10.40

11.07

31015/16/2023-

Pricing dated 27.05.2024

1547(E) dated 26.03.2024

(Sl. No. 369)

4

Montelukast

Tablet 4 mg

1

Tablet

10.03

10.23

31015/16/2023-

Pricing dated 27.05.2024

1547(E) dated 26.03.2024

(Sl. No. 464)

The notification further added,

  • All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (6) in the above table plus Goods and Services Tax as applicable, if any.
  • All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price specified in column (6) in the above table plus Goods and Services Tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
  • The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (6) of the above said table.
  • The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (6) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
  • As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
  • Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
  • The manufacturers of above said scheduled formulations shall furnish quarterly returns to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of the above-mentioned scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
  • The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
  • Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

Also Read:NPPA Fixes Retail Prices of 70 Formulations, Details

Powered by WPeMatico

West Bengal CM urges Central govt to establish fast-track courts for handling rape cases

In response to the nationwide outrage over the rape and murder of a postgraduate trainee at RG Kar Medical College in Kolkata, West Bengal Chief Minister Mamata Banerjee has urged the central government to introduce national legislation and establish fast-track courts for handling rape cases.
Urging the central government to bring in central legalization and set up fast-track courts for ”sensitive” issues, to ensure fast speedy trial, West Bengal Mamata Banerjee on Thursday wrote a letter to Prime Minister Narendra Modi in the wake of the national outrage over the RG Kar medical hospital incident where a second year trainee doctor was raped and murdered.
For more information, click on the link below:

Powered by WPeMatico

FAIMA ends strike against brutal rape-murder of Kolkata medico

In response to the Supreme Court’s directive, the Federation of All India Medical Associations (FAIMA) has called off its strike against the brutal rape and murder of a postgraduate medico at R G Kar Medical College Hospital in Kolkata.
In a self-made video message, FAIMA Chairman Dr Rohan Krishnan said that the protests will continue but in a different form.

For more information click on the link below:

Powered by WPeMatico

Synergistic mutations found in omicron variant of SARS-CoV-2

Certain changes in the genetic material of pathogens can alter their ability to infect human cells or protect them better from defense by the immune system. Researchers were able to observe this effect particularly impressively in the SARS-CoV-2 virus.

Powered by WPeMatico

Smallpox vaccination in childhood could offer protection against monkeypox clade II viruses, study finds

A study by co-authors from the ECDC, WHO and national public health institutes in four European countries, and published in Eurosurveillance, has found that prior smallpox vaccination in childhood could protect against infections caused by monkeypox virus (MPXV) clade II in men. However, the estimated degree of protection varied among countries, highlighting the need for further research to validate the study findings.

Powered by WPeMatico

Men infected with high-risk types of HPV could struggle with fertility

Cervical cancer, the fourth most common cancer type in women, causes approximately 350,000 deaths each year, mainly in middle- and low-income countries. Human papillomavirus (HPV) infection is known to cause 95% of these cases. Public health authorities in 37 countries currently vaccinate girls between nine and 14 years of age, before they typically start sexual activity.

Powered by WPeMatico